Inhibition of glucosylceramide synthase stimulates autophagy flux in neurons

Journal of Neurochemistry

Volumn 129, Issue 5, 2014, Pages 884-894

  Shen, Wei ^a   Henry, Anastasia G ^a   Paumier, Katrina L ^a   Li, Li ^a   Mou, Kewa ^a   Dunlop, John ^a   Berger, Zdenek ^a   Hirst, Warren D ^a  

^a PFIZER INC   (United States)

Author keywords

glucosylceramide; lysosome; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; CERAMIDE GLUCOSYLTRANSFERASE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; SMALL INTERFERING RNA;

ARTICLE; AUTOPHAGY; CELL COUNT; CELL SIZE; CONTROLLED STUDY; EMBRYO; ENDOSOME; ENZYME ACTIVITY; ENZYME INHIBITION; HEK293 CELL LINE; LYSOSOME; MOUSE; NERVE STIMULATION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

MAMMALIA;

GLUCOSYLCERAMIDE; LYSOSOME; PARKINSON'S DISEASE;

ANIMALS; AUTOPHAGY; BLOTTING, WESTERN; CELLS, CULTURED; DIOXANES; ENZYME INHIBITORS; FEMALE; GLUCOSYLTRANSFERASES; GLYCOSPHINGOLIPIDS; HEK293 CELLS; HUMANS; MALE; MEPERIDINE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NEURONS; ONCOGENE PROTEIN V-AKT; PARKINSON DISEASE; PHOSPHORYLATION; PRIMARY CELL CULTURE; PYRROLIDINES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

EID: 84901244111     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12672     Document Type: Article

References (55)

1. Ashe K. M., Bangari D., Li L., et al,. (2011) Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease. PLoS ONE 6, e21758.
2. Berger Z., Ravikumar B., Menzies F. M., et al,. (2006) Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum. Mol. Genet. 15, 433-442.
3. Cox T., Lachmann R., Hollak C., et al,. (2000) Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355, 1481-1485.
4. Cuervo A. M., Stefanis L., Fredenburg R., Lansbury P. T., and, Sulzer D., (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305, 1292-1295.
5. Futerman A. H., and, Hannun Y. A., (2004) The complex life of simple sphingolipids. EMBO Rep. 5, 777-782.
6. Giasson B. I., Duda J. E., Quinn S. M., Zhang B., Trojanowski J. Q., and, Lee V. M., (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34, 521-533.
7. Haack T. B., Hogarth P., Kruer M. C., et al,. (2012) Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA. Am. J. Hum. Genet. 91, 1144-1149.
8. Hara T., Nakamura K., Matsui M., et al,. (2006) Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 441, 885-889.
9. Hochfeld W. E., Lee S., and, Rubinsztein D. C., (2013) Therapeutic induction of autophagy to modulate neurodegenerative disease progression. Acta Pharmacol. Sin. 34, 600-604.
10. Jennemann R., Sandhoff R., Wang S., et al,. (2005) Cell-specific deletion of glucosylceramide synthase in brain leads to severe neural defects after birth. Proc. Natl Acad. Sci. USA 102, 12459-12464.
11. Jeyakumar M., Butters T. D., Cortina-Borja M., Hunnam V., Proia R. L., Perry V. H., Dwek R. A., and, Platt F. M., (1999) Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc. Natl Acad. Sci. USA 96, 6388-6393.
12. Juenemann K., and, Reits E. A., (2012) Alternative macroautophagic pathways. Int. J. Cell Biol. 2012, 189794.
13. Lachmann R. H., and, Platt F. M., (2001) Substrate reduction therapy for glycosphingolipid storage disorders. Expert Opin. Investig. Drugs 10, 455-466.
14. Larsen K. B., Lamark T., Overvatn A., Harneshaug I., Johansen T., and, Bjorkoy G., (2010) A reporter cell system to monitor autophagy based on p62/SQSTM1. Autophagy 6, 784-793.
15. Larsen S. D., Wilson M. W., Abe A., et al,. (2011) Property-based design of a glucosylceramide synthase inhibitor that reduces glucosyl-ceramide in the brain. J. Lipid Res. 53, 282-291.
16. Lee L., Abe A., and, Shayman J. A., (1999) Improved inhibitors of glucosylceramide synthase. J. Biol. Chem. 274, 14662-14669.
17. Levine B., and, Klionsky D. J., (2004) Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev. Cell 6, 463-477.
18. Levine B., and, Kroemer G., (2008) Autophagy in the pathogenesis of disease. Cell 132, 27-42.
19. Lukina E., Watman N., Arreguin E. A., et al,. (2010a) A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood 116, 893-899.
20. Lukina E., Watman N., Arreguin E. A., et al,. (2010b) Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood 116, 4095-4098.
21. Mazzulli J. R., Xu Y. H., Sun Y., Knight A. L., McLean P. J., Caldwell G. A., Sidransky E., Grabowski G. A., and, Krainc D., (2011) Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37-52.
22. Mosbech M. B., Kruse R., Harvald E. B., Olsen A. S., Gallego S. F., Hannibal-Bach H. K., Ejsing C. S., and, Faergeman N. J., (2013) Functional loss of two ceramide synthases elicits autophagy-dependent lifespan extension in C. elegans. PLoS ONE 8, e70087.
23. Nakai A., Yamaguchi O., Takeda T., et al,. (2007) The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat. Med. 13, 619-624.
24. Natoli T. A., Smith L. A., Rogers K. A., et al,. (2010) Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat. Med. 16, 788-792.
25. Nazio F., Strappazzon F., Antonioli M., et al,. (2013) mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self-association and function through AMBRA1 and TRAF6. Nat. Cell Biol. 15, 406-416.
26. Nishida Y., Arakawa S., Fujitani K., et al,. (2009) Discovery of Atg5/Atg7-independent alternative macroautophagy. Nature 461, 654-658.
27. Paumier K. L., Sukoff Rizzo S. J., Berger Z., et al,. (2013) Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's disease. PLoS ONE 8, e70274. doi: 10.1371/journal.pone.0070274.
28. Petiot A., Ogier-Denis E., Blommaart E. F., Meijer A. J., and, Codogno P., (2000) Distinct classes of phosphatidylinositol 3'-kinases are involved in signaling pathways that control macroautophagy in HT-29 cells. J. Biol. Chem. 275, 992-998.
29. Ravikumar B., Duden R., and, Rubinsztein D. C., (2002) Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum. Mol. Genet. 11, 1107-1117.
30. Rodriguez-Navarro J. A., Rodriguez L., Casarejos M. J., Solano R. M., Gomez A., Perucho J., Cuervo A. M., Garcia de Yebenes J., and, Mena M. A., (2010) Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation. Neurobiol. Dis. 39, 423-438.
31. Rose C., Menzies F. M., Renna M., Acevedo-Arozena A., Corrochano S., Sadiq O., Brown S. D., and, Rubinsztein D. C., (2010) Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's disease. Hum. Mol. Genet. 19, 2144-2153.
32. Saitsu H., Nishimura T., Muramatsu K., et al,. (2013) De novo mutations in the autophagy gene WDR45 cause static encephalopathy of childhood with neurodegeneration in adulthood. Nat. Genet. 45, 445-449.
33. Sarkar S., Floto R. A., Berger Z., Imarisio S., Cordenier A., Pasco M., Cook L. J., and, Rubinsztein D. C., (2005) Lithium induces autophagy by inhibiting inositol monophosphatase. J. Cell Biol. 170, 1101-1111.
34. Sarkar S., Davies J. E., Huang Z., Tunnacliffe A., and, Rubinsztein D. C., (2007a) Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J. Biol. Chem. 282, 5641-5652.
35. Sarkar S., Perlstein E. O., Imarisio S., et al,. (2007b) Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat. Chem. Biol. 3, 331-338.
36. Sarkar S., Korolchuk V., Renna M., Winslow A., and, Rubinsztein D. C., (2009a) Methodological considerations for assessing autophagy modulators: a study with calcium phosphate precipitates. Autophagy 5, 307-313.
37. Sarkar S., Ravikumar B., Floto R. A., and, Rubinsztein D. C., (2009b) Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. Cell Death Differ. 16, 46-56.
38. Scarlatti F., Bauvy C., Ventruti A., Sala G., Cluzeaud F., Vandewalle A., Ghidoni R., and, Codogno P., (2004) Ceramide-mediated macroautophagy involves inhibition of protein kinase B and up-regulation of beclin 1. J. Biol. Chem. 279, 18384-18391.
39. Schubert K. M., Scheid M. P., and, Duronio V., (2000) Ceramide inhibits protein kinase B/Akt by promoting dephosphorylation of serine 473. J. Biol. Chem. 275, 13330-13335.
40. Seglen P. O., and, Gordon P. B., (1982) 3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. Proc. Natl Acad. Sci. USA 79, 1889-1892.
41. Sillence D. J., Puri V., Marks D. L., Butters T. D., Dwek R. A., Pagano R. E., and, Platt F. M., (2002) Glucosylceramide modulates membrane traffic along the endocytic pathway. J. Lipid Res. 43, 1837-1845.
42. Spilman P., Podlutskaya N., Hart M. J., Debnath J., Gorostiza O., Bredesen D., Richardson A., Strong R., and, Galvan V., (2010) Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS ONE 5, e9979.
43. Stein V. M., Crooks A., Ding W., et al,. (2012) Miglustat improves purkinje cell survival and alters microglial phenotype in feline Niemann-Pick disease type C. J. Neuropathol. Exp. Neurol. 71, 434-448.
44. Sun Y., and, Grabowski G. A., (2010) Impaired autophagosomes and lysosomes in neuronopathic Gaucher disease. Autophagy 6, 648-649.
45. Taniguchi C. M., Kondo T., Sajan M., Luo J., Bronson R., Asano T., Farese R., Cantley L. C., and, Kahn C. R., (2006) Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta. Cell Metab. 3, 343-353.
46. Webb J. L., Ravikumar B., Atkins J., Skepper J. N., and, Rubinsztein D. C., (2003) Alpha-Synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 278, 25009-25013.
47. Williams A., Sarkar S., Cuddon P., et al,. (2008) Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Nat. Chem. Biol. 4, 295-305.
48. Xilouri M., Vogiatzi T., Vekrellis K., and, Stefanis L., (2008) alpha-synuclein degradation by autophagic pathways: a potential key to Parkinson's disease pathogenesis. Autophagy 4, 917-919.
49. Xilouri M., Vogiatzi T., Vekrellis K., Park D., and, Stefanis L., (2009) Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLoS ONE 4, e5515.
50. Xilouri M., Brekk O. R., Landeck N., Pitychoutis P. M., Papasilekas T., Papadopoulou-Daifoti Z., Kirik D., and, Stefanis L., (2013) Boosting chaperone-mediated autophagy in vivo mitigates alpha-synuclein-induced neurodegeneration. Brain 136, 2130-2146.
51. Yang Z., and, Klionsky D. J., (2010) Mammalian autophagy: core molecular machinery and signaling regulation. Curr. Opin. Cell Biol. 22, 124-131.
52. Yu L., McPhee C. K., Zheng L., et al,. (2010) Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature 465, 942-946.
53. Zervas M., Somers K. L., Thrall M. A., and, Walkley S. U., (2001) Critical role for glycosphingolipids in Niemann-Pick disease type C. Curr. Biol. 11, 1283-1287.
54. Zhao H., Przybylska M., Wu I. H., Zhang J., Siegel C., Komarnitsky S., Yew N. S., and, Cheng S. H., (2007) Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes 56, 1210-1218.
55. Zhao H., Przybylska M., Wu I. H., et al,. (2009) Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice. Hepatology 50, 85-93.